Both authors contributed equally.
Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper
Version of Record online: 9 MAR 2011
© 2011 John Wiley & Sons A/S
Volume 66, Issue 7, pages 840–844, July 2011
How to Cite
Baiardini, I., Braido, F., Bindslev-Jensen, C., Bousquet, P. J., Brzoza, Z., Canonica, G. W., Compalati, E., Fiocchi, A., Fokkens, W., Gerth van Wijk, R., Giménez-Arnau, A., Godse, K., Grattan, C., Grob, J. J., La Grutta, S., Kalogeromitros, D., Kocatürk, E., Lombardi, C., Mota-Pinto, A., Ridolo, E., Saini, S. S., Sanchez-Borges, M., Senna, G. E., Terreehorst, I., Todo Bom, A., Toubi, E., Bousquet, J., Zuberbier, T. and Maurer, M. (2011), Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper. Allergy, 66: 840–844. doi: 10.1111/j.1398-9995.2011.02580.x
Edited by: Hans-Uwe Simon
- Issue online: 1 JUN 2011
- Version of Record online: 9 MAR 2011
- Accepted for publication 15 February 2011
- 16US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research and US Department of Health and Human Services FDA Center for Devices and Radiological Health, Guidance for industry: patient reported outcome measures: use in medical product development to support labelling claims: draft guidance. Health Qual Life Outcomes 2006;4:79.
- 17European Medicines Agency. Committee for medicinal products for human use (CHMP). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQoL) measures in the evaluation of medicinal products. EMEA/CHMP/EWP/139391/2004 European Medicines Agency website. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf. Accessed October 2010.